The Pharma Data

JANUARY 5, 2021

Targeting RNA is believed to be a way to develop therapeutics for so-called undruggable proteins. This is because many proteins do not have small-molecule binding sites. So therapeutics that focus on RNA are designed to stop the DNA from coding for disease-causing proteins. Most Read Today. Source link.

RNA 52

RNA Protein Bioavailability DNA 52

Delveinsight

FEBRUARY 16, 2021

With damages to the bone marrow, the production and normal functioning of red blood cells, white blood cells, and platelets get hampered. Padcev is a first-in-class antibody-drug conjugate (ADC) directed against Nectin-4, a protein. The therapy is the first therapy of its kind to target the Nectin-4 protein.

Marketing 52

Marketing Protein Bioavailability Drugs 52

The Pharma Data

NOVEMBER 22, 2020

Alzprotect co-owns or has an exclusive worldwide license from the French National Institute of Health and Medical research (Inserm) and the University of Lille (France) on a total of 58 patents related to Ezeprogind in 39 countries. EZEPROGIND, which is kicking off phase 2a trials, is a bioavailable neurotrophic inducer.

Drugs 40

Drugs Protein Bioavailability Development 40

Delveinsight

JANUARY 7, 2021

The immunotherapy pipeline is led by an in-licensed EP4 antagonist that Ikena is testing combined with Keytruda in phase 1b/2 colorectal and non-small cell lung cancer clinical trials. Ikena will back a pipeline that falls into two categories. Hologic acquires Biotheranostics for USD 230 Million. Medical technology company Hologic Inc.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

The Pharma Data

DECEMBER 9, 2020

Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc., The company plans to do this by developing drugs that eliminate protein aggregation by either reducing the production of toxic proteins or removing them after the fact through autophagy. SciNeuro Pharmaceuticals.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52